Completed PHASE3 INTERVENTIONAL 2-arm NCT01465828

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial (RESET GENE)

PhaRmacodynamic Effects of Switching thErapy in paTients With High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel RESET GENE Trial

Sponsor: Gennaro Sardella

Conditions Acute Coronary Syndrome

Interventions Clopidogrel prasugrel

Updated 5 times since 2017 Last updated: Mar 24, 2012 Started: Oct 31, 2011 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Coronary Syndrome, this trial is completed. The trial is conducted by Gennaro Sardella and has accumulated 5 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gennaro Sardella

Data source: University of Roma La Sapienza

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roma, Italy
• Rome, Italy